Literature DB >> 26025226

Clinical profile and main comorbidities of Spanish adults with Down syndrome.

Diego Real de Asua1, Miriam Quero2, Fernando Moldenhauer3, Carmen Suarez4.   

Abstract

BACKGROUND: The life expectancy of adults with Down syndrome (DS) has significantly increased in the last decades. We aim to describe the main demographic and clinical characteristics of a cohort of adults with DS, and analyse their differences according to age and gender groups.
METHODS: Cross-sectional study of 144 adults with DS from the outpatient clinic of a tertiary care hospital in Madrid, Spain, recruited between February 2012 and March 2013. Demographic data (age, gender, living situation, caregivers, and working situation), clinical conditions, prior medications, and laboratory data were measured and compared between groups.
RESULTS: Adults with DS were 35±12 years old (range 17-65), and 51% were males. Most subjects lived with their families (112, 78%), and parents were the main caregivers in 73% of cases. However, older adults with DS lived more frequently in residential facilities. Each subject presented an average of 5±2 clinical problems. Eye (117 adults, 81%), skin (86, 60%), thyroid (81, 56%), gastrointestinal (73, 51%), and psychopathological disorders (58, 40%) were amongst the most frequent clinical conditions of adults with DS. Cataracts (14, 61%), keratoconus (4, 17%), dementia (11, 48%), and seizures (6, 26%) were more frequent amongst individuals with DS over 50 years (p<0.001 for the comparisons). No relevant differences were found between genders. The medications most frequently prescribed were levothyroxine (70 subjects, 48.6%), vitamin D (50, 34.7%), antidepressants (32, 22%), and antipsychotics (31, 21.5%).
CONCLUSIONS: Adults with DS present a wide spectrum of potentially treatable medical conditions, making specially-trained multidisciplinary teams a dire need for this population.
Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comorbidity; Dementia; Down syndrome; Hypothyroidism; Obesity

Mesh:

Year:  2015        PMID: 26025226     DOI: 10.1016/j.ejim.2015.05.003

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  11 in total

1.  Diverging results of areal and volumetric bone mineral density in Down syndrome.

Authors:  M García-Hoyos; M T García-Unzueta; D de Luis; C Valero; J A Riancho
Journal:  Osteoporos Int       Date:  2016-11-12       Impact factor: 4.507

2.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 3.  Changes in bone mineral density in Down syndrome individuals: a systematic review and meta-analysis.

Authors:  Y Zhang; Z Tian; S Ye; Q Mu; X Wang; S Ren; X Hou; W Yu; J Guo
Journal:  Osteoporos Int       Date:  2021-08-12       Impact factor: 4.507

4.  Trisomy 21 impairs PGE2 production in dermal fibroblasts.

Authors:  John O Marentette; Colin C Anderson; Kendra M Prutton; Erin Q Jennings; Abhishek K Rauniyar; James J Galligan; James R Roede
Journal:  Prostaglandins Other Lipid Mediat       Date:  2021-01-05       Impact factor: 3.072

Review 5.  Molecular and Histopathological Changes Associated with Keratoconus.

Authors:  Mariam Lotfy Khaled; Inas Helwa; Michelle Drewry; Mutsa Seremwe; Amy Estes; Yutao Liu
Journal:  Biomed Res Int       Date:  2017-01-30       Impact factor: 3.411

Review 6.  RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target.

Authors:  Shuai Wang; Yuqing Wang; Kaixin Qiu; Jin Zhu; Yili Wu
Journal:  Mol Med       Date:  2020-12-02       Impact factor: 6.354

Review 7.  Prevalence of keratoconus in persons with Down syndrome: a review.

Authors:  Olav Kristianslund; Liv Drolsum
Journal:  BMJ Open Ophthalmol       Date:  2021-04-21

8.  Sleep and White Matter in Adults with Down Syndrome.

Authors:  Victoria Fleming; Brianna Piro-Gambetti; Austin Bazydlo; Matthew Zammit; Andrew L Alexander; Bradley T Christian; Benjamin Handen; David T Plante; Sigan L Hartley
Journal:  Brain Sci       Date:  2021-10-05

Review 9.  Adults with Down syndrome challenge another paradigm: When aging no longer entails arterial hypertension.

Authors:  Emilia Roy-Vallejo; José María Galván-Román; Fernando Moldenhauer; Diego Real de Asúa
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-09       Impact factor: 3.738

Review 10.  Thyroid Disorders in Subjects with Down Syndrome: An Update.

Authors:  Nermine H Amr
Journal:  Acta Biomed       Date:  2018-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.